Personalized infliximab dosing to help children with Crohn's disease reach deep remission
Precise Infliximab Exposure and Pharmacodynamic Control to Achieve Deep Remission in Pediatric Crohn's Disease
This project uses personalized infliximab dosing and a clinician dashboard to help children and teens with Crohn's disease get better intestinal healing and longer-lasting remission.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Cincinnati Childrens Hosp Med Ctr NIH-funded |
| Lab location | 1 site (Cincinnati, United States) |
| Project ID | NIH-11323130 on NIH RePORTER |
What this research studies
If your child starts or is already on infliximab, doctors will use blood tests and an online dosing dashboard to calculate a tailored dose right from the first infusion. They will regularly check drug levels and markers of immune activity and adjust dosing to keep drug exposure in a range linked to healing. The approach uses a pharmacokinetic model to guide those dose decisions rather than fixed schedules. The team aims to increase steroid-free remission and endoscopic healing compared with standard dosing.
Who could benefit from this research
Good fit: Children and adolescents under 18 with moderate to severe Crohn's disease who are starting or receiving infliximab are the most likely candidates.
Not a fit: Children whose disease is not driven by TNF biology, who cannot receive infliximab due to allergies or other contraindications, or who are being treated with non-switchable biologics may not benefit.
Why it matters
Potential benefit: If successful, this could raise the chances that children on infliximab achieve deeper intestinal healing and stay in steroid-free remission.
How similar studies have performed: Previous work using therapeutic drug monitoring and dose optimization has improved remission and intestinal healing, and this project applies model-informed precision dosing to extend those gains.
Where this research is happening
Cincinnati, United States
- Cincinnati Childrens Hosp Med Ctr — Cincinnati, United States (Active)
Researchers
- Principal investigator: Minar, Phillip P — Cincinnati Childrens Hosp Med Ctr
- Study coordinator: Minar, Phillip P
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.